Xu Z, et al. - For previously treated advanced non-small cell lung cancer (NSCLC), nivolumab (an inhibitor of programmed death-1 [PD-1] protein) vs docetaxel-based chemotherapy were tested in terms of efficacy as a second-line treatment via this systematic review and meta-analysis of six studies including 949 patients. Via searches of databases and conference proceedings, researchers identified relevant studies and evaluated primary endpoints which included progression-free survival (PFS), overall survival (OS), drug responses, and adverse effects (AEs). Compared to docetaxel-based chemotherapy, both anti-tumor efficacy and safety displayed by nivolumab proved it a better therapy for advanced NSCLC. The 10 AEs mostly experienced by patients treated with nivolumab were fatigue (15.7%), nausea (10.8%), decreased appetite (10.3%), asthenia (9.8%), diarrhea (7.5%), rash (7.5%), arthralgia (5.4%), vomiting (4.4%), constipation (3.5%), and pyrexia (3.3%).